We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Manganese-Based Contrast Agent Could Make MRI Safer

By HospiMedica International staff writers
Posted on 29 Aug 2019
A novel Manganese-based contrast agent may provide tumor contrast enhancement comparable to that of gadolinium-based contrast agents (GBCAs), according to a new study.

Developed at Massachusetts General Hospital (MGH; Boston, USA), Harvard Medical School (HMS; Boston, MA, USA), and the Institute for Innovation in Imaging (i3; Boston, MA), Mn-PyC3A takes advantage of the fact that unlike gadolinium, manganese is an essential element that is naturally found in the body. More...
The Manganese in Mn-PyC3A is tightly bound to a chelating agent, which prevents it from interacting with cells or proteins in an adverse way, and also allows for rapid elimination from the body after the imaging exam.

For the study, the researchers compared the efficacy of Mn-PyC3A to two state of the art GBCAs in detecting tumors in two mouse models, breast cancer and metastatic live cancer. They found that the tumor contrast enhancement provided by Mn-PyC3A was comparable to the performance of the two GBCAs. They also found that the fractional excretion and elimination of Mn-PyC3A in a rat model was superior to that of GBCAs, with 85% eliminated into the urine and the remaining 15 percent eliminated in the feces. The study was published on July 25, 2019, in Investigative Radiology.

“About 40 percent of MRI procedures use a contrast agent to produce a signal that can detect cancers, diagnose aneurysms or arterial narrowing, or identify the area of a heart damaged by a heart attack,” said senior co-author Peter Caravan, PhD, co-director of i3. “We estimate that around two million contrast-enhanced scans are not performed in the United States every year because of the inability to use GBCAs in patients with poor renal function. Mn-PyC3A could make MRI safer.”

There are two forms of GBCAs; the less stable linear GBCAs, which are more toxic, and the more stable macrocyclic GBCAs, which is safer. It is has been established that gadolinium deposits in three main brain areas, the dentate nucleus of the cerebellum, the globus pallidus and the pulvinar. Outside of the brain, gadolinium deposition occurs in the kidney, where it can cause nephrogenic systemic fibrosis, a scleroderma-like disorder; this, however, occurs mostly in people with renal impairment. Harm from gadolinium deposition has not been established.

Related Links:
Massachusetts General Hospital
Harvard Medical School
Institute for Innovation in Imaging


Gold Member
Neonatal Heel Incision Device
Tenderfoot
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Monitor/Defibrillator
Zenix
Pediatric Mask
Respire SOFT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Design-science framework integrating CML and LLM pipelines for supply chain risk evaluation. (Gupta I, Konduru H, Correa S, et al. A causal analytics approach for interpretable supply chain risk and supplier performance evaluation. Supply Chain Analytics, 2026. doi:10.1016/j.sca.2026.100248)

Causal AI Tool Withholds Ovarian Cancer Treatment Recommendations When Evidence Insufficient

Ovarian cancer treatment often requires individualized decisions, particularly when available patient data do not clearly favor one therapeutic approach. However, artificial intelligence (AI) systems may... Read more

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.